利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.053 秒)

    Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
    3.
    发明申请
    Pharmaceutical formulations for carrier-mediated transport statins and uses thereof 有权
    用于载体介导的运输他汀类药物的制剂及其用途

    公开(公告)号：US20050119331A1

    公开(公告)日：2005-06-02

    申请号：US10967167

    申请日：2004-10-19

    申请人： Jackie Butler ,  John Devane ,  Paul Stark

    发明人： Jackie Butler ,  John Devane ,  Paul Stark

    IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K31/40 ,  A61K31/505 ,  A61K31/401 ,  A61K31/225 ,  A61K31/366

    CPC分类号： A61K31/505 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/284 ,  A61K9/2846 ,  A61K31/40 ,  C07D207/34

    摘要： The present invention relates to formulations comprising therapeutically effective amounts of at least one acid-stable, carrier-mediated transport statin, at least one poorly water-soluble, carrier-mediated transport statin, or at least one large molecular weight, carrier-mediated transport statin, such as atorvastatin and rosuvastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to exhibit a controlled-release of a therapeutic amount of the statin in the small intestine, thereby limiting systemic exposure of the statin and maximizing liver-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.

    摘要翻译： 本发明涉及包含治疗有效量的至少一种酸稳定的载体介导的转运他汀类药物，至少一种难溶于水的载体介导的转运他汀类药物或至少一种大分子量的载体介导的转运体 他汀类药物，如阿托伐他汀和罗苏伐他汀，或其药学上可接受的盐及其使用方法。 本发明的制剂和方法设计用于在小肠中显示治疗量的他汀类药物的受控释放，从而限制他汀类药物的全身暴露并使药物的肝脏特异性吸收最大化。 本发明的制剂和方法特别可用于治疗和/或预防通过降低体内脂质和/或胆固醇水平而受益的病症。

    Pravastatin pharmaceutical formulations and methods of their use
    4.
    发明申请
    Pravastatin pharmaceutical formulations and methods of their use 审中-公开
    普伐他汀药物制剂及其使用方法

    公开(公告)号：US20050277691A1

    公开(公告)日：2005-12-15

    申请号：US11205028

    申请日：2005-08-17

    申请人： Jackie Butler ,  John Devane ,  Paul Stark

    发明人： Jackie Butler ,  John Devane ,  Paul Stark

    IPC分类号： A61K9/20 ,  A61K9/22 ,  A61K9/28 ,  A61K31/22 ,  A61K31/225 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P43/00

    CPC分类号： A61K9/284 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/2886 ,  A61K31/22 ,  A61K31/225

    摘要： The present invention relates to formulations comprising a therapeutically effective amount of pravastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to release little or no pravastatin in the stomach but release a therapeutic amount of pravastatin in the small intestine, thereby limiting systemic exposure of the body to pravastatin and maximizing hepatic-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.

    摘要翻译： 本发明涉及包含治疗有效量的普伐他汀或其药学上可接受的盐的制剂及其使用方法。 本发明的制剂和方法被设计为在胃中释放很少或没有普伐他汀，但在小肠中释放治疗量的普伐他汀，从而限制身体对普伐他汀的全身暴露并最大限度地提高药物的肝特异性吸收。 本发明的制剂和方法特别可用于治疗和/或预防通过降低体内脂质和/或胆固醇水平而受益的病症。

    Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
    5.
    发明授权
    Pharmaceutical formulations for carrier-mediated transport statins and uses thereof 有权
    用于载体介导的运输他汀类药物的制剂及其用途

    公开(公告)号：US08987322B2

    公开(公告)日：2015-03-24

    申请号：US10967167

    申请日：2004-10-19

    申请人： Jackie Butler ,  John Devane ,  Paul Stark

    发明人： Jackie Butler ,  John Devane ,  Paul Stark

    IPC分类号： A61K31/40 ,  A61K9/28 ,  A61K9/20 ,  A61K31/505 ,  C07D207/34

    CPC分类号： A61K31/505 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/284 ,  A61K9/2846 ,  A61K31/40 ,  C07D207/34

    摘要： The present invention relates to formulations comprising therapeutically effective amounts of at least one acid-stable, carrier-mediated transport statin, at least one poorly water-soluble, carrier-mediated transport statin, or at least one large molecular weight, carrier-mediated transport statin, such as atorvastatin and rosuvastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to exhibit a controlled-release of a therapeutic amount of the statin in the small intestine, thereby limiting systemic exposure of the statin and maximizing liver-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.

    摘要翻译： 本发明涉及包含治疗有效量的至少一种酸稳定的载体介导的转运他汀类药物，至少一种难溶于水的载体介导的转运他汀类药物或至少一种大分子量的载体介导的转运体 他汀类药物，如阿托伐他汀和罗苏伐他汀，或其药学上可接受的盐及其使用方法。 本发明的制剂和方法设计用于在小肠中显示治疗量的他汀类药物的受控释放，从而限制他汀类药物的全身暴露并使药物的肝脏特异性吸收最大化。 本发明的制剂和方法特别可用于治疗和/或预防通过降低体内脂质和/或胆固醇水平而受益的病症。

    Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin
    6.
    发明申请
    Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin 审中-公开
    包含头孢菌素的纳米颗粒和控释组合物

    公开(公告)号：US20090269400A1

    公开(公告)日：2009-10-29

    申请号：US11568825

    申请日：2006-05-16

    申请人： John Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Rekhi ,  Scott Jenkins ,  Gary Liversidge

    发明人： John Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Rekhi ,  Scott Jenkins ,  Gary Liversidge

    IPC分类号： A61K9/48 ,  A61K9/20 ,  A61K9/10 ,  A61K9/14 ,  A61K9/50 ,  A61P19/10 ,  A61K31/545 ,  A61K31/546

    CPC分类号： A61K9/14 ,  A61K9/1676 ,  A61K9/5078

    摘要： The present invention is directed to compositions comprising a nanoparticulate antibiotic having improved bioavailability. Preferably, the antibiotic comprises nanoparticulate cephalosporin particles with an effective average particle size of less than about 2000 nm and are useful in the treatment of bacterial infection. The invention also relates to a controlled release composition comprising a cephalosporin or a nanoparticulate cephalosporin that in operation delivers the drug in a pulsed or bimodal manner for the treatment of bacterial infection. The nanoparticulate cephalosporin particles may be formulated as a controlled release drug delivery system whereby the particles are coated one or more times with one or more natural or synthetic hydrophilic or hydrophobic polymer coating materials or dispersed throughout a natural or synthetic hydrophilic and/or hydrophobic polymer matrix.

    摘要翻译： 本发明涉及包含具有改善的生物利用度的纳米颗粒抗生素的组合物。 优选地，抗生素包含有效平均粒度小于约2000nm的纳米微粒头孢菌素颗粒，并且可用于治疗细菌感染。 本发明还涉及包含头孢菌素或纳米微粒头孢菌素的控释组合物，其在操作中以脉冲或双峰方式递送药物用于治疗细菌感染。 纳米颗粒头孢菌素颗粒可以配制成控释药物递送系统，由此颗粒用一种或多种天然或合成的亲水或疏水性聚合物涂层材料涂覆一次或多次，或分散在整个天然或合成的亲水和/或疏水性聚合物基质中 。

    Multiparticulate modified release composition
    9.
    发明申请
    Multiparticulate modified release composition 审中-公开
    多微粒改性组合物

    公开(公告)号：US20060240105A1

    公开(公告)日：2006-10-26

    申请号：US11372857

    申请日：2006-03-10

    申请人： John Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Rekhi ,  Scott Jenkins ,  Gary Liversidge

    发明人： John Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Rekhi ,  Scott Jenkins ,  Gary Liversidge

    IPC分类号： A61K31/485 ,  A61K31/192 ,  A61K9/26

    CPC分类号： A61K31/485 ,  A61K9/501 ,  A61K9/5015 ,  A61K9/5026 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/192

    摘要： The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers at least one active ingredient in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition.

    摘要翻译： 本发明涉及一种多微粒改性释放组合物，其在给予患者时以双峰或多峰方式递送至少一种活性成分。 多微粒改性组合物包含第一组分和至少一个后续组分; 所述第一组分包含含有颗粒的第一组活性成分和所述至少一种随后组分，所述至少一种后续组分包含含有颗粒的第二组活性成分，其中所述组分的组合表现出双峰或多峰释放曲线。 本发明还涉及含有这种多微粒改性释放组合物的固体口服剂型。